# Madrigal Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/madrigal-pharmaceuticals

- Industry: Biotechnology
- Headquarters: US
- Website: www.madrigalpharma.com
- Total disclosed funding: $10M
- Latest round: Seed (Sep 1, 2011)
- Investors on record: 1

## About

Based in Pennsylvania, US, and founded in 2016 by CMO Rebecca Taub, Madrigal Pharmaceuticals, Inc. operates as a biopharmaceutical company providing novel therapeutics for non-alcoholic steatohepatitis, a liver disease with high unmet medical need. As of 2024, the company is listed on Nasdaq with ticker MDGL. In March 2024, Madrigal Pharmaceuticals, Inc. raised USD 195 million in a private placement, selling 750,000 shares at USD 260 apiece on the Nasdaq Global Select Market. In addition, Underwriters were granted a 30-day option to purchase up to an additional 346,153 shares.

Madrigal Pharmaceuticals, Inc. provides a liver-directed thyroid hormone receptor (THR) ß-selective agonist, designed to target the underlying causes of NASH. The company offers oral medication by reducing liver fat (steatosis), inflammation, and fibrosis, which are key factors in the progression of NASH. The therapy is in Phase 3 clinical trials, for patients with compensated cirrhosis. In addition, the firm provides a solution to improve liver health and prevent the severe complications associated with advanced NASH.

## Funding rounds

- Seed, Sep 1, 2011, $10M — Bay City Capital

## Investors

- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Seed